-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Some people say that "doing the subtraction of life" is a positive attitude to life, get rid of the "redundancy" of burden, return to your own heart, you will live a brisk and free
life.
The ancient Greek philosopher Epicotita said that happiness in one's life should come from being as dependent as
possible on foreign things.
For patients with lupus nephritis, hormone reduction may be one of the most anticipated subtractions, but for doctors and patients, hormone reduction is tantamount to a 108,000-mile flame mountain, which is difficult
.
On August 27, a series of live broadcasts initiated by the "Physician Daily" - the third issue of the decoding lupus nephritis expert living room, the art of subtraction - how lupus patients can reduce recurrence + hormone reduction
.
The event was presided over
by Zhang Yanping, executive president and executive editor-in-chief of Physician Newspaper.
The program was simultaneously broadcast live on platforms such as Doctor Daily Live Broadcast Center Medical TV, Doctor Daily Video Account, Weibo Health, Relief Grocery Store Video Account, Baidu Health, Sina News Client and other platforms, with a total of 227,000 views
.
Chen Chaosheng
Biologics help patients with lupus nephritis in early remission
Professor Chen Chaosheng, chairman of the conference and the First Affiliated Hospital of Wenzhou Medical University, said that great progress has been made in the etiology, pathogenesis, diagnosis and treatment of lupus nephritis, and the emergence of bioagents has made the safety of lupus nephritis patients have been strongly guaranteed
.
Professor Chen Chaosheng introduced that the latest "KDIGO Clinical Practice Guidelines" (hereinafter referred to as the guidelines) requires different treatment plans
to be given according to different pathological manifestations in the treatment of lupus nephritis.
Control the activity of lupus and lupus nephritis as soon as possible, and achieve complete remission
for patients with lupus nephritis within half a year to one year.
During treatment, it is necessary to pay attention to the side effects of the drug, and to be able to control lupus activity on the basis of minimizing the amount and time
of hormones.
At the same time, the guidelines also emphasize that we should pay attention to the maintenance treatment of lupus nephritis, reduce the side effects of treatment to patients, and improve the quality of life
of patients.
The emergence of biologics has brought new options
to patients with lupus nephritis.
Guidelines state that biologics such as belimumab
can be added during the induction phase of lupus nephritis.
Early application of biologics in the treatment of lupus nephritis can help patients achieve better outcomes
.
Ai Jun
Detail the side effects of traditional treatments
Professor Ai Jun of Nanfang Hospital of Southern Medical University introduced that the application of hormones and immunosuppressants has greatly improved the prognosis of patients, but also brought some side effects, such as infection, peptic ulcer and other problems
.
The use of glucocorticoids can also bring about disorders of lipid metabolism, glucose metabolism, bone metabolism and physical appearance in
patients.
Data show that patients with lupus nephritis continue to take hormones for one year, and 57% of patients have necrosis
of the femoral head of varying severity.
In addition to hormones, cyclophosphamide is also a drug
that nephrologists "love and hate".
Professor Ai Jun said that it has been used for the treatment of lupus for more than 50 years and is one of the commonly used first-line drugs for the treatment of
lupus nephritis.
However, cyclophosphamide has more serious side effects and can lead to menstrual disorders and amenorrhea in women, oligospermia and azoospermia
in men.
It can be said that cyclophosphamide opens a window to the treatment of lupus nephritis, and may also close the door
to fertility.
Traditional treatments offer hope for disease relief in patients with lupus nephritis, but there are still many unmet needs
.
Professor Ai Jun hopes that with the promotion of biosuppressants, better treatment plans can emerge to effectively meet the needs of
patients.
Xiao Li
Patients with lupus nephritis do not have to "talk about hormonal discoloration"
Professor Xiao Li of the Second Xiangya Hospital of Central South University introduced that hormones are a chemical with high efficiency information transmission produced by endocrine cells, which plays an important role in regulating the metabolism, growth and development of the body
.
During treatment, the amount of hormones ingested far exceeds the normal body-generated dose, which can produce side effects such as osteoporosis, high blood sugar, necrosis of the femoral head, and increase the risk of
infection and cardiovascular system disease.
Professor Xiao Li believes that although there are many hormonal side effects, regular monitoring, rational use of drugs, and timely dose reduction can reduce toxic side effects, and patients with lupus nephritis do not need to "talk about hormonal discoloration"
.
"In addition, some patients with lupus nephritis also have the idea
of 'taking hormones for life'.
" Professor Xiao Li introduced that with the advancement of treatment methods, there are many ways to maintain the stability of various indicators in the remission period of lupus nephritis, and the future will gradually enter the "hormone-free era"
.
Li Shaomei
How to achieve renal remission with low doses of hormones?
Professor Li Shaomei of the Second Hospital of Hebei Medical University said that long-term application of hormones will cause a burden
on the patient's body.
In the routine treatment of lupus patients, about 50% of patients develop complications, which are one of the causes of
disability and death.
At present, lupus cannot be completely cured, and patients need long-term treatment
.
How to reduce the amount of hormones while maintaining the relief and stability of lupus nephritis, Professor Li Shaomei introduced that a large number of research data prove that belimumab can effectively help hormone reduction, and can effectively reduce hormone dosage while maintaining kidney remission
.
The combination of belimumab during the induction period can reduce the hormone to a low level in half a year, and can reduce the risk
of recurrence by 55% compared with lupus nephritis patients who do not use belimumab during the induction period.
"As a drug for the treatment of chronic diseases, long-term efficacy and safety are clearly of great concern
.
Belimumab has a unique evidence advantage
in this regard.
Professor Li Shaomei said that from the real-world use of belimumab for ten years, the side effects of belimumab are low and the safety is reliable
.
Liu Zhengzhao
Lose hormones, do not relapse, what can we do?
In the clinical treatment of lupus nephritis, there are two types of landmark drugs, one is hormones and the other is immunosuppressants
.
The application of hormones has greatly reduced the mortality rate of patients with lupus nephritis and improved the quality of life of patients, but the side effects caused by hormones
cannot be ignored.
Clinicians are relentless in finding ways to
reduce hormone dosing.
Professor Liu Zhengzhao of Jinling Hospital affiliated to Nanjing University believes that the side effects and use of hormones are directly related
.
At present, the peak amount of oral hormones is low and rapidly reduced during the induction period of lupus nephritis treatment, and the minimum measured hormone or no hormones
are pursued during the maintenance period of lupus nephritis.
Professor Liu Zhengzhao introduced that in the traditional means, high-dose methylprednisolone impact can help patients achieve hormone reduction in the induction period
.
In recent years, new immunosuppressants and biological inhibitors have emerged, playing a certain role
in the induction and maintenance period of lupus nephritis.
Clinical studies have shown that the recurrence rate of lupus nephritis with belimumab in the maintenance period is 10% lower than that of patients in the hormone group, which can effectively help patients reduce hormone dosage and reduce toxic side effects
.
Belimumab landed in China, bringing a new model
of low-hormone therapy to patients with lupus nephritis.
Liu Qinghua
Biologics will be the next milestone in the treatment of lupus nephritis
Belimumab is a fully human monoclonal antibody that targets the binding of soluble B lymphocyte stimulating factor through intravenous administration, inhibits the proliferation and differentiation of B cells, induces autoreactive B cell apoptosis, thereby reducing autoantibodies in serum and achieving the purpose of
treating systemic lupus erythematosus and lupus nephritis.
Professor Liu Qinghua of the First Affiliated Hospital of Sun Yat-sen University introduced that a clinical trial that is currently being carried out has shown that the main remission rate of belimumab in patients with lupus nephritis can reach 100%, and the complete remission rate can reach 83%.
The safety and efficacy of belimumab have been verified many times, Professor Liu Qinghua believes that the treatment of lupus nephritis induction period, the use of hormones combined with belimumab, can effectively reduce the amount of hormones, and the application of belimumab in the remission period can effectively reduce the recurrence rate
.
He said that with the continuous improvement of medical standards, the treatment of lupus nephritis has undergone continuous development
from hormones and immunosuppressants.
Bioagents are expected to be the next milestone
in the treatment of patients with lupus nephritis.
Typesetting: Liu Zebo
Editor: Liu Zebo
Reviewed: Lina Wang
The power to move the industry forward! The report of the 7th Medical Scientist Summit 2022 is here!
The 2022 "Physician Daily" is under order!!! Millions of doctors are watching.
.
.
"Physician Daily" public mailbox: yishibao2017@163.
com
[Note] Some pictures come from the Internet and WeChat Moments, if there is infringement, please contact to delete, thank you! Tel: 010-58302828-6808
At present, 1130000+ doctors have paid attention to join us
